BAIT

ADE2

phosphoribosylaminoimidazole carboxylase ADE2, L000000032, YOR128C
Phosphoribosylaminoimidazole carboxylase; catalyzes a step in the 'de novo' purine nucleotide biosynthetic pathway; red pigment accumulates in mutant cells deprived of adenine
GO Process (3)
GO Function (1)
GO Component (1)
Saccharomyces cerevisiae (S288c)
PREY

HPT1

BRA6, hypoxanthine phosphoribosyltransferase, HGPRTase, HPRT, L000004313, YDR399W
Dimeric hypoxanthine-guanine phosphoribosyltransferase; catalyzes the transfer of the phosphoribosyl portion of 5-phosphoribosyl-alpha-1-pyrophosphate to a purine base (either guanine or hypoxanthine) to form pyrophosphate and a purine nucleotide (either guanosine monophosphate or inosine monophosphate); mutations in the human homolog HPRT1 can cause Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome
GO Process (2)
GO Function (1)
GO Component (2)

Gene Ontology Biological Process

Gene Ontology Molecular Function

Gene Ontology Cellular Component

Saccharomyces cerevisiae (S288c)

Phenotypic Suppression

A genetic interaction is inferred when mutation or over expression of one gene results in suppression of any phenotype (other than lethality/growth defect) associated with mutation or over expression of another gene.

Publication

Lethal accumulation of guanylic nucleotides in Saccharomyces cerevisiae HPT1-deregulated mutants.

Breton A, Pinson B, Coulpier F, Giraud MF, Dautant A, Daignan-Fornier B

Guanylic nucleotide biosynthesis is a conserved and highly regulated process. Drugs reducing GMP synthesis affect the immunological response and mutations enabling guanylic-derivative recycling lead to severe mental retardation. While the effects of decreased GMP synthesis have been well documented, the consequences of GMP overproduction in eukaryotes are poorly understood. In this work, we selected and characterized several mutations making yeast ... [more]

Genetics Feb. 01, 2008; 178(2);815-24 [Pubmed: 18245832]

Throughput

  • Low Throughput

Ontology Terms

  • phenotype: nutrient utilization (APO:0000096)

Additional Notes

  • hpt1 suppresses the inability of a guk1 ade2 mutant to use hypoxanthine as a purine source.

Related interactions

InteractionExperimental Evidence CodeDatasetThroughputScoreCurated ByNotes
HPT1 ADE2
Negative Genetic
Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

High-0.8033BioGRID
370439
ADE2 HPT1
Negative Genetic
Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

High-0.6525BioGRID
2184316
HPT1 ADE2
Negative Genetic
Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

High-0.7894BioGRID
2101419
ADE2 HPT1
Negative Genetic
Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

High-0.4338BioGRID
535323
HPT1 ADE2
Negative Genetic
Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

High-0.2784BioGRID
535616

Curated By

  • BioGRID